After three decades of unsuccessful efforts to develop small molecules that neutralize the cancer-causing Ras proteins, an approach has been found that opens up fresh avenues for anticancer research. See Letter p.548
References
Baines, A. T., Xu, D. & Der, C. J. Future Med. Chem. 3, 1787–1808 (2011).
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. & Shokat, K. M. Nature 503, 548–551 (2013).
Thompson, H. Nature Med. 19, 949–950 (2013).
Rowinsky, E. K. J. Clin. Oncol. 24, 2981–2984 (2006).
Zimmermann, G. et al. Nature 497, 638–642 (2013).
Maurer, T. et al. Proc. Natl Acad. Sci. USA 109, 5299–5304 (2012).
Sun, Q. et al. Angew. Chem. Int. Edn 51, 6140–6143 (2012).
Shima, F. et al. Proc. Natl Acad. Sci. USA 110, 8182–8187 (2013).
Sequist, L. V. et al. J. Clin. Oncol. 31, 3327–3334 (2013).
Byrd, J. C. et al. N. Engl. J. Med. 369, 32–42 (2013).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Bollag, G., Zhang, C. Pocket of opportunity. Nature 503, 475–476 (2013). https://doi.org/10.1038/nature12835
Published:
Issue Date:
DOI: https://doi.org/10.1038/nature12835
- Springer Nature Limited
This article is cited by
-
AIMP2-DX2 provides therapeutic interface to control KRAS-driven tumorigenesis
Nature Communications (2022)
-
An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer
Nature Communications (2017)